Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is as sociated with shorter overall survival than other breast cancer subtypes, despite the use of curative-intent anthracycline- and taxane-based systemic chemotherapy. Neoadjuvant therapy is now also recognized as the standard treatment for patients with high-risk TNBC. The Keynote-522 study demonstrated that the application of pembrolizumab has raised the pathological Complete Response (pCR) rate in TNBC to over 60%, but nearly 40% of patients still do not achieve pCR. How to further improve the pCR rate in TNBC patients has become a hot topic of current

Trial Details

NCT ID

NCT06802757

Phase

PHASE2

Sponsor

Shandong Cancer Hospital and Institute

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• Posaconazole
• Nab-paclitaxel
• Carboplatin
• Anthracycline
• Cyclophosphamide
• PD-1 inhibitors

Locations (sample)

• Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

• Female, aged ≥ 18 and ≤ 70 years old;
• first-confirmed TNBC;
• cT1cN1-3M0 or cT2-4N0-3M0;
• ECOG score 0-1 points.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →